Prescribing guide
Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl (efanesoctocog alfa))Weekly prophylaxis, bleed and perioperative dosing, inhibitor and FVIII assay monitoring, and prior authorization criteriaFor prescribers and their offices treating hemophilia A: what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No REMS and no boxed warning; prior authorization, HemAssist enrollment online or by fax, specialty pharmacy shipment and IV infusion training before the first home dose.
Example PA threshold
Cigna example: hemophilia specialist; FVIII inhibitor test within 30 days under 1.0BU/mL or no prior FVIII; prophylaxis up to 50IU/kg no more than weekly; 1-year approvals.
Monitoring
Clinical and laboratory monitoring for FVIII inhibitors; measure FVIII activity with a one-stage clotting assay (chromogenic overestimates about 2.5-fold); watch for hypersensitivity.
Support line
Sanofi HemAssist, 1-833-723-5463, Monday to Friday 8 AM to 7 PM ET, fax 1-855-398-7634; commercial copay as little as $0; Free Trial first 30-day supply; Patient Assistance Program.
Give your patient their plan
A one-page handout for starting Altuviiio, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/altuviiioBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Enroll in HemAssist | Enroll online, or fax the ALTUVIIIO enrollment form to 1-855-398-7634. If the patient cannot consent in the office, HemAssist can reach out for consent directly. | HemAssist enrollment |
| Benefits investigation | A HemAssist Case Manager verifies coverage and screens for financial programs. Sanofi's checklist flags confirming medical vs. pharmacy benefit first; Cigna's policy here applies to medical benefit coverage. | PA checklist |
| PA packet | Sanofi suggests diagnosis documentation, a letter of medical necessity (template available), labs, bleed logs, inhibitor testing if applicable, genetic testing or family history, and current and prior products. | PA checklist |
| Free Trial | First-time patients can receive a 30-day supply, generally within 24 to 48 hours of a valid prescription. Once per patient per product lifetime; not valid in Vermont; not billable to any payer. | HemAssist |
| Specialty pharmacy | HemAssist helps coordinate delivery and can triage the prescription to the specialty pharmacy if the office prefers. Sanofi's pages do not name a pharmacy network. | HemAssist enrollment |
| Train the patient or caregiver | The Patient Information says not to self-inject until taught by a provider or hemophilia center, and the provider may watch the first self-dose. Counsel on hypersensitivity signs and on reporting a lack of clinical response. | FDA label |
| Supplemental training | HemAssist Clinical Educators offer supplemental infusion training and dosing education in the first months; they do not give personal medical advice. | HemAssist |
| Order supplies | Each kit holds 1 single-dose vial, a prefilled syringe with 3mL sterile water and a vial adapter. Multi-vial doses are pooled into a larger luer lock syringe, which is not in the carton; an infusion set is also needed. | FDA label |
| Copay enrollment | Commercial plans only, as little as $0, enrolled through the HemAssist copay portal. Excludes Medicare including Part D, Medicaid, Medigap, VA, DoD, TRICARE and state pharmaceutical assistance programs. | HemAssist enrollment |
Prior authorization criteria and what to document
One public policy as the example: Cigna, May 1, 2026. Approval one year at a time; renewal asks for an inhibitor test in the past 365 days or the prescriber's word that there are no signs of inhibitors. This policy took effect on May 1, 2026 and cites the December 2025 Altuviiio label, which is still the current text. It covers Altuviiio under the medical benefit. Citing MASAC guidance, it allows prevention doses plus 3 days of bleed or surgery doses per 28 days, and larger amounts get a case review. It is here as an example of what a plan asks for, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Use | Routine prophylaxis, on-demand treatment and control of bleeding episodes, or perioperative management of bleeding | Treatment plan in the note | Cigna policy |
| Inhibitor status, initial | FVIII inhibitor test within the past 30 days and no positive result of 1.0BU/mL or higher, or no prior FVIII therapy | Bethesda result with date, or treatment history | Cigna policy |
| Inhibitor status, continuation | Inhibitor test within the past 365 days under 1.0BU/mL, or the prescriber states no clinical signs of inhibitors | Result with date, or a statement on bleed control and FVIII response | Cigna policy |
| Prescriber | Prescribed by or in consultation with a hemophilia specialist | Specialty on the request, or HTC consult note | Cigna policy |
| Prophylaxis dosing | Up to 50IU/kg IV no more frequently than once weekly | Current weight and the weekly dose | Cigna policy |
| Bleed and surgical dosing | Up to 50IU/kg, with additional doses every 2 to 3 days for up to 10 days per episode or procedure | Home dose quantity; amounts above prophylaxis plus 3 days of treatment per 28 days go to case review | Cigna policy |
| Supporting records | Sanofi's checklist adds bleed logs, labs, genetic testing or family history and prior products | Attach to the first request | PA checklist |
Altuviiio dosing and titration
| When | Label | Source |
|---|---|---|
| Routine prophylaxis | 50IU/kg IV once weekly, adults and children. No pediatric dose adjustment. | FDA label |
| Minor or moderate bleed | Single 50IU/kg dose; 30IU/kg may be used within 2 to 3 days after a prophylactic dose. Additional 30 or 50IU/kg every 2 to 3 days may be considered. | FDA label |
| Major bleed | Single 50IU/kg dose (intracranial, retroperitoneal, iliopsoas, neck, compartment syndrome, significant hemoglobin drop). Additional 30 or 50IU/kg every 2 to 3 days can be considered. | FDA label |
| Resuming prophylaxis | At least 72 hours between the last 50IU/kg treatment dose and the next prophylactic dose, then the usual schedule. | FDA label |
| Minor surgery | Single 50IU/kg pre-operative dose (for example tooth extraction); an additional 30 or 50IU/kg after 2 to 3 days may be considered. | FDA label |
| Major surgery | Single 50IU/kg pre-operative dose; additional 30 or 50IU/kg every 2 to 3 days as clinically needed. | FDA label |
| Target-level formula | Dose (IU) = weight (kg) × desired FVIII rise (IU/dL) × 0.5. Expected peak rise from 50IU/kg is about 100IU/dL. | FDA label |
| Kits | 250 (yellow, 71104-978-01), 500 (red, -979-01), 750 (garnet, -980-01), 1000 (green, -981-01), 2000 (royal blue, -982-01), 3000 (mist grey, -983-01), 4000IU (orange, -984-01). Not all pack sizes may be marketed. | FDA label |
| Administration | IV over 1 to 10 minutes; use within 3 hours of reconstitution; do not refrigerate after mixing; not in the same tubing or container as other medications. | FDA label |
| Pharmacokinetics | Half-life 48.2 hours in adults, 44.6 at 12 to under 18, 42.4 at 6 to under 12, 38.0 at 1 to under 6. FVIII above 40IU/dL for a mean 4.1 days in adults; above 10IU/dL about 7 days in children under 12. | FDA label |
| Storage | 2°C to 8°C in the original package, not frozen. Room temperature up to 30°C for a single period of up to 6 months, dated on the carton; do not return to the refrigerator. | FDA label |
Monitoring the Altuviiio label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Any time | FVIII inhibitors | Monitor clinically and by laboratory tests. If FVIII levels do not rise as expected or bleeding is not controlled, test with a Bethesda assay. Reported postmarketing; none detected in the trials. Section 5.2 revised 12/2025. | FDA label |
| When FVIII activity is measured | One-stage clotting assay | Chromogenic and a specific ellagic acid based aPTT reagent overestimate about 2.5-fold; divide by 2.5. Use a reference laboratory if no qualified assay is available locally. | FDA label |
| Any infusion | Hypersensitivity, including anaphylaxis | Hives, shortness of breath, chest tightness, wheezing, hypotension, nausea, vomiting, itching. Discontinue Altuviiio and manage symptoms. Contraindicated after severe hypersensitivity to the product or excipients. | FDA label |
| Long-term | Thromboembolic events | 1% (3/261) in the long-term extension study; all 3 had pre-existing risk factors. | FDA label |
| Any time | Common adverse reactions | Headache 15% and arthralgia 13% pooled (N = 233); adults and adolescents 20.1% and 16.4%; pyrexia 12.2% most common under 12. | FDA label |
| Renewal | Inhibitor status | Cigna continuation needs an inhibitor test within 365 days or the prescriber's statement of no clinical signs of inhibitors. | Cigna policy |
Altuviiio drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Other drugs | The label has no drug interactions section and lists no interaction studies. | FDA label |
| Co-administration | Do not administer reconstituted Altuviiio in the same tubing or container with other medications. | FDA label |
| FVIII assays | Chromogenic and a specific ellagic acid based aPTT one-stage reagent overestimate Altuviiio activity about 2.5-fold. Potency is assigned by an aPTT-based one-stage clotting assay. | FDA label |
| Von Willebrand disease | Not indicated for the treatment of von Willebrand disease. | FDA label |
| Pregnancy and lactation | No human data and no animal reproduction studies; no information on presence in human milk. | FDA label |
| Geriatric | Trials did not include enough patients 65 or older to tell whether response differs. | FDA label |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedSanofi lists incomplete paperwork, plan exclusions and missed step rules as common reasons. The office can call 1-833-723-5463 and ask for a local Field Reimbursement Manager.
- No recent inhibitor testCigna's policy below asks for an inhibitor test in the past 30 days for a first approval, under 1.0 Bethesda units/mL. People who never had factor VIII before are exempt from that test.
- The plan wants a hemophilia specialistCigna covers Altuviiio only when a hemophilia specialist prescribes it or is consulted. A note from your hemophilia treatment center can show this.
- The doses asked for are above the plan's limitCigna approves up to 50IU/kg no more than once a week for prevention. Bleed and surgery doses are approved every 2 to 3 days, for up to 10 days each time.
- The request went to the wrong benefitFactor products can be covered under a medical or a pharmacy benefit. Sanofi's checklist says a benefit check can find the right path to coverage.
- The prescription went to the wrong pharmacyHemAssist helps coordinate delivery, and it can send the prescription to the specialty pharmacy if the office prefers.
- A copay you cannot payWith commercial insurance, the Copay Assistance Program offers as little as $0. Medicare, Medicaid, Medigap, VA, DoD, TRICARE and state programs are excluded by its terms.
- No insurance, or a gap in coverageHemAssist's Patient Assistance Program may help people who are uninsured, underinsured or between plans. A Case Manager checks whether you qualify.
Sanofi HemAssist
- A Case Manager who calls within 24 hours of enrollment, checks your insurance and helps coordinate shipments
- A Copay Assistance Program for commercial insurance, as little as $0
- No copay help for Medicare, Medicaid, Medigap, VA, DoD, TRICARE or state programs
- A Free Trial Program with the first 30-day supply for first-time patients, once per lifetime, not valid in Vermont
- A Patient Assistance Program for people who are uninsured, underinsured or between plans
- A Clinical Educator for extra infusion training and tips during the first months
- Enrollment online, or by fax at 1-855-398-7634
Questions prescribers' offices ask about Altuviiio
What is the Altuviiio prophylaxis dose?
The December 2025 label gives 50IU/kg IV once weekly for adults and children, with no pediatric dose adjustment. Inject slowly over 1 to 10 minutes and use within 3 hours of reconstitution. Steady state kept FVIII above 40IU/dL for a mean 4.1 days in adults and 2 to 3 days in children under 12.
How is Altuviiio dosed for a bleed or surgery?
A single 50IU/kg dose for minor, moderate or major bleeds and before minor or major surgery, per the December 2025 label. For minor or moderate bleeds within 2 to 3 days of a prophylactic dose, 30IU/kg may be used. Further doses of 30 or 50IU/kg every 2 to 3 days may be considered; allow at least 72 hours after the last 50IU/kg treatment dose before resuming prophylaxis.
Which FVIII activity assay should be used with Altuviiio?
A validated one-stage clotting assay, per the December 2025 label. The chromogenic assay and a specific ellagic acid based aPTT reagent overestimate Altuviiio activity about 2.5-fold; divide those results by 2.5. Use a reference laboratory if a qualified assay is not available locally.
Does Altuviiio require inhibitor monitoring?
Yes, for all patients: section 5.2 of the December 2025 label, revised 12/2025, reports postmarketing FVIII inhibitors and calls for clinical and laboratory monitoring. If FVIII levels fail to rise as expected or bleeding is not controlled, test for inhibitors in Bethesda Units. No inhibitors were detected in the trials.
What do insurers require for Altuviiio prior authorization?
Cigna's policy, effective May 1, 2026 and citing the December 2025 label, approves 1 year at a time. Initial approval needs an FVIII inhibitor test within 30 days under 1.0BU/mL, or no prior FVIII therapy, and a hemophilia specialist. Prophylaxis is capped at 50IU/kg no more than weekly; bleed and surgical doses every 2 to 3 days for up to 10 days.
Free email alert
Get an email when the Altuviiio label changes
One email the day the FDA revises the Altuviiio prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Altuviiio only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- DailyMed - ALTUVIIIO (antihemophilic factor- recombinant, fc-vwf-xten fusion protein-ehtl kit (prescribing information revised December 2025, Patient Information and Instructions for Use), Bioverativ Therapeutics Inc. (Sanofi), via DailyMed, 2026-10-20.
- Approved Risk Evaluation and Mitigation Strategies (REMS), FDA, 2026-11-08.
- ALTUVIIIO | FDA, FDA, Center for Biologics Evaluation and Research, 2025-12-31.
- Patient Support for ALTUVIIIO | Sanofi HemAssist, Sanofi, 2026-11-08.
- Enroll in Rare Blood Disorder Support | Sanofi HemAssist, Sanofi, 2026-11-08.
- Insurance and Financial aid for Rare Blood Disorder | Sanofi HemAssist, Sanofi, 2026-11-08.
- Prior Authorization Checklist, Sanofi, 2024-10-01.
- Hemophilia - Altuviiio, Drug Coverage Policy IP0564, Cigna, 2026-05-01.
- December 29, 2025 Approval Letter - ALTUVIIIO (STN BL 125771/643, inhibitor development, sections 5 and 6), FDA, 2025-12-29.
- March 7, 2025 Approval Letter - ALTUVIIIO (STN BL 125771/437, sections 5.1 and 6.2), FDA, 2025-03-07.
- May 10, 2024 Approval Letter - ALTUVIIIO (STN BL 125771/136, completed pediatric study results), FDA, 2024-05-10.
- February 22, 2023 Approval Letter - ALTUVIIIO (STN BL 125771/0), FDA, 2023-02-22.
A reference drawn from the October 20, 2026 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 8, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.